Valveclip® Transcatheter Mitral Valve Repair Study

Inclusion Criteria: 1. Severe mitral regurgitation≥3+ (moderate or above degenerative mitral regurgitation disease, or with stenosis is included); 2. Age≥70 years; or patients who are 60\~70 years old, and the STS risk score indicate that participants are at high risk of traditional surgery or cannot tolerate traditional thoracotomy; 4\) Left ventricular ejection fraction≥30%； 5) As assessed by multidisciplinary cardiac team (at least two cardiac surgeons/one cardiologist), patients who are at extremely high-risk or unsuitable for routine mitral valve surgery with evaluation; 6) Patients who understand the purpose of the trial and volunteer to participate in, sign the informed consent form and are willing to accept relevant examinations and clinical follow-ups. Anatomy selection Criteria： 1. The regurgitant jet of mitral valve originates from the A2 and P2 (the lesions of A2/P2 in mitral valve causes regurgitation); 2. The width of the mitral valve prolapsed area is ≤15mm, Height of Prolapse ≤10mm or coaptation depth≤11mm, coaptation height≥2mm, effective length of anterior and posterior leaflets\>1cm (conforming to EVEREST II recommended mitral valve interventional edge-to-edge repair standards); 3. Effective mitral valve orifice area≥ 4.0cm2; 4. No obvious calcification of the mitral valve annulus and valve leaflets; 5. Patient's anatomical conditions allow transseptal approach. Exclusion Criteria: 1. Previous cardiac mitral valve surgery; 2. Patients with Infective endocarditis or having an active infection; 3. Patients with mitral regurgitation caused by pure mitral stenosis; 4. Combined with untreated severe coronary artery disease 5. Pulmonary hypertension (pulmonary artery systolic pressure\>70mmHg); 6. Patients with severe right heart failure; 7. Patients are extremely weak and cannot tolerate general anesthesia or are in shock that circulatory support is needed; 8. Patients with hypertrophic cardiomyopathy, restrictive cardiomyopathy, and constrictive pericarditis; 9. Patients receiving chronic dialysis; 10. Patients with clear coagulation dysfunction and severe coagulopathy; 11. Patients with clear contraindications to anticoagulant drugs; 12. Patients with stroke or transient ischemic attack within 30 days; 13. Echocardiography found any intracardiac mass, left ventricle or atrial thrombus; 14. Patients who require surgery or interventional therapy for other valvular lesions; 15. Patients with severe macrovascular lesions requiring surgical treatment; 16. Patients' imaging examinations suggest that the anatomy of the heart and valves are inappropriate;